The biotech industry is brimming and making strides in personalized medicine and treatments for rare diseases. Biotech firms are leveraging cutting-edge technologies like gene editing, CRISPR, and AI to create tailored therapies that address specific genetic profiles and unmet medical needs.
Given this backdrop, investors could consider buying these fundamentally sound biotech stocks, Immunocore Holdings plc (IMCR), BioCryst Pharmaceuticals, Inc. (BCRX), and Harmony Biosciences Holdings, Inc. (HRMY) that are diving into the innovations.
